Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. [PDF]
Bionanoscience, 2022 Kirillova A, Lado A, Blatt N.
europepmc +1 more source
Interleukin-6 blocking agents for treating COVID-19: a living systematic review. [PDF]
Cochrane Database Syst Rev, 2023 Ghosn L +28 more
europepmc +1 more source
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). [PDF]
Int Immunopharmacol, 2022 Elahi R +3 more
europepmc +1 more source
Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. [PDF]
Open Forum Infect Dis, 2022 Wu Q +6 more
europepmc +1 more source
A Clinical Case of Nosocomial Pneumonia as a Complication of COVID-19: How to Balance Benefits and Risks of Immunosuppressive Therapy? [PDF]
Antibiotics (Basel), 2022 Rachina S +9 more
europepmc +1 more source
Inhalable antibodies for the treatment of COVID-19. [PDF]
Innovation (Camb), 2022 Yang Z, Li C, Song Y, Ying T, Wu Y.
europepmc +1 more source
Coronavirus Infection COVID-19 and Pregnancy. [PDF]
Her Russ Acad Sci, 2022 Kurtser MA.
europepmc +1 more source
Intensive Care of Patients with COVID-19. [PDF]
Her Russ Acad Sci, 2022 Petrikov SS, Popugaev KA, Zhuravel' SV.
europepmc +1 more source
Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. [PDF]
Hum Vaccin Immunother, 2021 Johnson AM, Barigye R, Saminathan H.
europepmc +1 more source
Acute Kidney Injury in Hospitalized Patients with COVID-19: Risk Factors and Serum Biomarkers. [PDF]
Biomedicines, 2023 Shchepalina A +12 more
europepmc +1 more source